More Data Supports Approval as Lifileucel Review for Melanoma Pushed Back
The new PDUFA date of lifileucel is set for Februrary 24, 2024.
Axi-Cel Improves Overall Survival in Lymphoma, ZUMA-7 Analysis Shows
Investigators plan to present full results from the OS analysis of the phase 3 ZUMA-7 trial at an upcoming medical meeting.
Ide-cel Beats SOC in Relapsed/Refractory Multiple Myeloma PFS
Progression free survival and overall response rate were higher in patients with R/R MM treated with Abecma than those treated with standard of care.
Celyad Discontinues CYAD-101 for Metastatic Colorectal Cancer
The decision comes after a previous clinical hold delayed key medical milestones in the KEYNOTE-B79 trial.
Cilta-Cel Yields High MRD-Negativity Rates in Multiple Myeloma After Prior Anti-BCMA Treatment
Seven of 10 evaluable patients achieved minimal residual disease negativity after cilta-cel treatment.
Lentiviral CAR T Therapy Delivers Good Efficacy, Safety in R/R Multiple Myeloma
Participants in the trial achieved a sustained response and experienced low-grade toxicity.
CAR Macrophage Cell Therapy for HER2 Solid Tumors Enters Human Trials
CT-0508 was granted a fast track designation in September 2021 for use as a potential therapy for patients with solid tumors.
R/R Multiple Myeloma CAR T-Cell Therapy Receives Orphan Drug Designation
CT103A is co-developed by IASO Biotherapeutics and Innovent Biologics.
Liso-Cel Improved Quality of Life in Second-Line LBC Lymphoma
Patients in the liso-cel arm had more favorable overall least square mean changes from baseline to day 126 vs the SOC arm in quality of life scores.
Cilta-Cel Improves Survival in R/R Multiple Myeloma Over Physician Choice of Treatment
Patients treated with cilta-cel had a 76% reduction in the risk of death compared to patients treated with physician's choice of treatment.